Media Coverage

Kane Biotech sets its sights on European market entry


Dec 07, 2017 - Animal Pharm
By Joseph Harvey
Animal Pharm
December 7, 2017


Canadian business Kane Biotech wants to take its companion animal oral care products to the European sector.

The company's StrixNB portfolio is already on sale in North America through a partnership with Dechra Pharmaceuticals. Under the terms of this deal, StrixNB is marketed as Vetradent by Dechra.

The next step for Winnipeg-based Kane is to seek out licensing and distribution partners based in Europe, the firm's president and chief executive Mark Ahrens-Townsend told Animal Pharm.

He pointed out Kane's products are the safest way to approach oral care in companion animals. Mr Ahrens-Townsend said there is a lack of safe and clinically-proven products available for tackling oral problems in companion animals.

The company's chief executive also pointed out StrixNB is free from potentially dangerous ingredients such as xylitol, alcohol, chlorophyll, chlorhexidine, chlorophyllin copper, green tea extract, grape seed, grapefruit seed and yucca extract – something other oral care products in pets cannot claim.

He said StrixNB has been clinically proven through independent trials to reduce tartar by 25% within two or three months, and it significantly reduces halitosis even more quickly.

According to Kane, 80% of dogs and cats will face dental disease within the first three years of their lives. Additionally, periodontal disease is the number one disease in dogs and cats. The firm sites industry sources that indicate the pet oral care market in the US was estimated to be worth around $775 million in 2015 and growing rapidly. This suggests the market is now a billion-dollar opportunity in just the US.

The StrixNB product line is available as a water additive, oral spray, powder and toothpaste. All of the products are approved by Health Canada's Low Risk Veterinary Health Products program. Each formulation has been created using Kane's proprietary coactive+ technology that breaks down biofilm and destroys bacteria.

Founded in 2001, Kane has 71 patents and patents pending. This makes it a leader in biofilm research in both animal health and human health.


Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum